No definition available.
Neuroendocrine tumor and carcinoma of lung, excluding all cancers (controls excluding all cancers)
C3_LUNG_NEUROENDO_EXALLC
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
259 |
4. Check minimum number of eventsNone |
259 |
5. Include endpointsNone |
259 |
6. Filter based on genotype QC (FinnGen only) |
259 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Neuroendocrine tumor and carcinoma of lung, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Neuroendocrine tumor and carcinoma of lung
- Malignant neoplasm of bronchus and lung
- Malignant neoplasm of respiratory system and intrathoracic organs
- Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)
- Lung cancer and mesothelioma
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 259 | 162 | 97 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.04 |
| Median age at first event (years) | 64.80 | 64.11 | 65.96 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 232
- Matched controls
- 2321
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
237.4
123.5
118
10
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
29.2
92.9
136
107
C34.37
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung carcinoid
+∞
75.2
68
*
C34.17
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary carcinoid
+∞
70.5
64
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
23.8
66.1
99
70
GDC01
NOMESCO Finland
Thoracoscopic lobectomy of lung
+∞
62.4
57
*
130
Kela drug reimbursment
Malignant tumour
+∞
62.4
57
*
8240/3-C34.9
ICD-O-3
Neuroendocrine tumor, NOS, of lung, NOS
+∞
58.9
54
*
8240/3-C34.3
ICD-O-3
Neuroendocrine tumor, NOS, of lower lobe, lung
+∞
49.8
46
*
GDC00
NOMESCO Finland
Lobectomy of lung
520.2
44.8
43
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
18.1
35.2
56
40
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.8
33.9
163
674
8240/3-C34.1
ICD-O-3
Neuroendocrine tumor, NOS, of upper lobe, lung
+∞
33.1
31
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
32.8
31.5
41
15
WZC30
NOMESCO Finland
Teaching
7.9
29.4
74
129
WX302
NOMESCO Finland
Thoracal epidural anesthesy
36.4
29.2
37
12
C34.27
ICD-10 Finland
Malignant tumor of the middle lobe, bronchus or lung carcinoid
+∞
25.5
24
*
H02AB02
ATC
dexamethasone; systemic
35.5
24.4
31
10
8246/3-C34.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of lung, NOS
+∞
24.4
23
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
23.3
22
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
23.3
22
*
JN4BD
NOMESCO Finland
Extensive body CT
11.3
22.8
44
47
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
21.2
20
*
C34.97
ICD-10 Finland
Malignant tumor in unspecified location in bronchial and pulmonary carcinoid
+∞
20.1
19
*
C34.1
ICD-10 Finland
Malignant neoplasm: Upper lobe, bronchus or lung
+∞
20.1
19
*
A04AA02
ATC
granisetron; systemic, transdermal
114.9
19.9
21
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.9
19.6
74
204
GDB21
NOMESCO Finland
Thoracoscopic segmental resection of lung
+∞
19.0
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
206.0
18.8
19
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
17.9
17
*
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
194.2
17.8
18
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
46.0
17.6
21
5
JN4CD
NOMESCO Finland
Very extensive body CT
19.8
16.9
25
14
8246/3-C34.1
ICD-O-3
Neuroendocrine carcinoma, NOS, of upper lobe, lung
+∞
16.9
16
*
Z51.5
ICD-10 Finland
Palliative care
20.4
16.4
24
13
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
9.1
16.0
34
43
C34.30
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung without histology
+∞
15.8
15
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.7
15.6
81
292
B01AB05
ATC
enoxaparin; parenteral
3.3
15.2
101
440
GD1AD
NOMESCO Finland
Thorax CT examination
9.5
15.1
31
37
GDB11
NOMESCO Finland
Thoracoscopic wedge resection of lung
85.7
14.8
16
*
L01CB01
ATC
etoposide; systemic
+∞
14.7
14
*
C34.90
ICD-10 Finland
Malignant tumor in unspecified location in bronchus and lung without histology
+∞
14.7
14
*
8240/3-C34.2
ICD-O-3
Neuroendocrine tumor, NOS, of middle lobe, lung
+∞
14.7
14
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.5
14.7
57
157
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
38.8
14.7
18
5
N02AX02
ATC
tramadol; systemic, rectal
3.0
14.3
127
665
JN4AD
NOMESCO Finland
Body CT examination
9.1
14.3
30
37
115
Kela drug reimbursment
Breast cancer
+∞
13.7
13
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
13.7
13
*
8249/3-C34.3
ICD-O-3
Neuroendocrine tumor, grade 2 of lower lobe, lung
+∞
13.7
13
*
PJA12
NOMESCO Finland
Sentinel node biopsy
148.3
13.6
14
*
XX3DW
NOMESCO Finland
Time consuming IT work
7.6
13.2
31
46
WX402
NOMESCO Finland
General anaesthesia
4.1
13.1
55
163
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
15.3
13.0
21
15
R4110
NOMESCO Finland
Physiotherapy
3.1
13.0
88
379
C34.87
ICD-10 Finland
Malignant overall tumor of bronchial and pulmonary carcinoid
+∞
12.6
12
*
8249/3-C34.1
ICD-O-3
Neuroendocrine tumor, grade 2 of upper lobe, lung
+∞
12.6
12
*
TGD00
NOMESCO Finland
Needle biopsy of lung
137.1
12.6
13
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.5
12.1
64
227
L03AA13
ATC
pegfilgrastim; parenteral
+∞
11.6
11
*
C34.99
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary other or unspecified histology
+∞
11.6
11
*
C34.39
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung other or unspecified histology
+∞
11.6
11
*
N03AX16
ATC
pregabalin; oral
2.9
11.0
83
376
A04AA01
ATC
ondansetron; systemic, rectal
12.1
10.8
19
17
WF002
NOMESCO Finland
Radical radiotherapy
115.0
10.5
11
*
C34.19
ICD-10 Finland
Malignant tumor of the upper lobe, bronchus or lung other or unspecified histology
+∞
10.5
10
*
E34.0
ICD-10 Finland
Carcinoid syndrome
+∞
10.5
10
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
9.4
9
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
9.4
9
*
HAB40
NOMESCO Finland
Wedge excision of mammary gland
+∞
9.4
9
*
C34.9
ICD-10 Finland
Malignant neoplasm: Bronchus or lung, unspecified
+∞
9.4
9
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
9.4
9
*
C34.10
ICD-10 Finland
Malignant tumor of the upper lobe, bronchus or lung without histology
+∞
9.4
9
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
9.4
9
*
L01BC06
ATC
capecitabine; oral
+∞
9.4
9
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.1
9.2
36
99
R03BB04
ATC
tiotropium bromide; inhalant
3.3
8.7
45
156
A02BC02
ATC
pantoprazole; systemic
2.4
8.5
164
1170
R84
ICPC
Malignant neoplasm bronchus/lung
93.3
8.5
9
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
8.4
8
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
8.4
8
*
C34.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bronchus and lung
+∞
8.4
8
*
H01CB03
ATC
lanreotide; parenteral
+∞
8.4
8
*
C34.15
ICD-10 Finland
Malignant tumor of the anterior, bronchial or lung other non-microcellular carcinoma
+∞
8.4
8
*
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
7.3
8.3
19
28
R04.2
ICD-10 Finland
Haemoptysis
7.4
7.9
18
26
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.5
7.9
73
360
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.5
7.8
27
66
N02AA05
ATC
oxycodone; systemic
3.2
7.7
42
148
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.7
7.5
32
95
R03AK08
ATC
formoterol and beclometasone; inhalant
5.3
7.5
22
45
L02BA01
ATC
tamoxifen; oral
82.6
7.5
8
*
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
82.6
7.5
8
*
D14.3
ICD-10 Finland
Benign neoplasm: Bronchus and lung
82.6
7.5
8
*
XG410
NOMESCO Finland
Flow-volume spirometry
5.8
7.4
20
37
C34.00
ICD-10 Finland
Malignant tumor of the main bronchus without histology
+∞
7.3
7
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
7.3
7
*
GDA20
NOMESCO Finland
Excision of lesion of lung
+∞
7.3
7
*
JN7AQ
NOMESCO Finland
Somatostatin receptor SPET med low dose CT
+∞
7.3
7
*
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
+∞
7.3
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.3
7
*
C34.32
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung adenocarcinoma
+∞
7.3
7
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
7.3
7
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
7.3
7
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.3
7
*
R03AC02
ATC
salbutamol; inhalant
2.1
7.3
133
893
HA1AA
NOMESCO Finland
X-ray mammography
7.1
6.9
16
24
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
6.5
6.9
17
28
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.4
6.8
67
340
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
41.3
6.8
8
*
GD5CD
NOMESCO Finland
Thorax and upper abdomen combined very extensive CT examination of
41.3
6.8
8
*
UGC18
NOMESCO Finland
Flexible bronchoscopy with biopsy of lung
41.3
6.8
8
*
J01MA12
ATC
levofloxacin; systemic
2.7
6.7
49
212
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
6.5
50
223
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
3.0
6.5
38
144
A79
ICPC
Malignancy NOS
71.7
6.5
7
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
6.3
6
*
A04AD12
ATC
aprepitant; systemic
+∞
6.3
6
*
C34.07
ICD-10 Finland
Malignant tumor of the main bronchus carcinoid
+∞
6.3
6
*
H01CB02
ATC
octreotide; parenteral
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
8246/3-C34.3
ICD-O-3
Neuroendocrine carcinoma, NOS, of lower lobe, lung
+∞
6.3
6
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
6.3
6
*
PJD99
NOMESCO Finland
Excision of other lymph nodes
+∞
6.3
6
*
GCA05
NOMESCO Finland
Bronchoscopic laser therapy of lesion of bronchus
+∞
6.3
6
*
C34.16
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary microcellular carcinoma
+∞
6.3
6
*
GDC20
NOMESCO Finland
Lobectomy of lung and sleeve resection of bronchus
+∞
6.3
6
*
L01AX03
ATC
temozolomide; systemic
+∞
6.3
6
*
GAB10
NOMESCO Finland
Antero- or postero-lateral thoracotomy
+∞
6.3
6
*
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
+∞
6.3
6
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
27.5
6.3
8
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
39
24
18.95
47.07
1.3
1.0
—
—
—
0
0
64
105
7.77
39.52
2.6
1.4
26.09
5.38
ug/l
0.42
56
84
40
38
12.27
37.59
1.3
1.4
—
—
—
0
0
30
26
12.92
29.68
1.2
1.3
—
—
—
0
0
194
1104
4.02
22.29
10.5
6.0
4.22
4.20
e9/l
0.06
176
962
191
1215
3.18
15.51
6.2
4.5
6.98
6.78
mmol/l
0.64
183
1120
31
64
5.37
14.68
2.6
2.9
—
—
—
0
0
95
427
2.93
14.64
2.4
1.9
—
—
—
0
0
159
934
2.82
14.64
7.8
5.1
1.22
1.22
mmol/l
0.37
151
830
148
841
2.77
14.50
4.8
3.5
34.63
35.86
g/l
1.80
141
776
149
872
2.67
13.42
3.6
3.7
—
—
—
0
0
165
1023
2.69
13.09
9.1
5.4
1.21
1.22
mmol/l
0.42
141
868
12
0
+∞
12.60
2.9
0.0
57.15
—
pmol/l
—
12
0
60
227
3.14
12.33
7.9
8.0
1.14
1.31
mmol/l
0.15
55
185
217
1588
3.26
11.87
13.3
5.3
85.34
75.61
u/l
2.28
212
1464
119
656
2.51
11.70
4.8
2.0
2.39
2.35
mmol/l
1.84
108
532
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
23
53
4.67
9.54
2.7
2.4
0.27
0.38
u/ml
—
10
28
39
149
2.90
7.72
4.8
6.6
8.59
10.13
mmol/l
0.82
39
141
49
227
2.43
6.60
3.2
4.5
1.00
1.02
mmol/l
0.20
49
203
9
6
15.47
5.94
1.2
1.0
—
—
—
0
0
67
376
2.05
5.62
3.9
2.1
2.49
2.44
mmol/l
2.76
62
313
13
34
3.97
4.59
2.8
2.9
3.74
4.80
e9/l
0.94
13
34
10
21
4.91
4.57
3.3
5.2
—
—
—
0
0
13
35
3.86
4.42
3.3
3.5
56.15
60.54
%
0.66
13
35
101
703
1.72
4.14
3.7
2.8
—
—
—
0
0
82
539
1.76
4.11
3.8
2.8
0.64
0.50
e6/l
0.24
61
392
189
1574
1.74
3.82
5.1
4.3
15.27
11.99
mm/h
1.77
179
1423
10
25
4.12
3.73
1.1
1.3
—
—
—
0
0
32
159
2.16
3.64
2.2
3.5
100.16
75.04
ng/l
1.48
32
139
15
52
3.00
3.52
1.2
1.6
139.14
131.97
g/l
—
7
35
54
328
1.82
3.48
3.1
2.5
0.70
1.21
e6/l
1.03
28
186
20
83
2.53
3.40
5.2
3.9
24.91
24.99
mmol/l
0.04
20
74
50
299
1.83
3.39
3.3
2.7
2.57
3.37
e6/l
0.15
26
158
67
441
1.70
3.27
1.7
1.7
1.76
0.96
mg/l
1.00
55
347
10
34
3.02
2.44
1.3
1.3
—
—
—
0
0
228
2083
1.79
2.43
25.0
11.9
31.82
21.91
mg/l
3.66
215
1583
6
12
5.09
2.41
1.0
1.0
—
—
—
0
0
194
1708
1.54
2.36
31.2
14.2
14.10
13.60
%
4.03
194
1667
31
190
1.72
1.95
1.7
1.8
1.32
1.53
%
1.35
26
167
33
209
1.66
1.85
1.7
1.7
—
—
—
0
0
22
124
1.85
1.82
2.8
1.3
—
—
—
0
0
5
13
3.90
1.72
3.0
1.5
1.10
1.06
g/l
—
5
13
44
305
1.53
1.71
1.8
1.7
—
—
—
0
0
10
42
2.44
1.70
1.1
1.4
147.50
65.99
pmol/l
—
10
42
87
690
1.39
1.69
2.5
2.9
1172.73
1436.05
ng/l
0.36
76
583
7
25
2.85
1.66
1.7
1.2
—
—
—
0
0
11
49
2.30
1.66
1.8
1.6
—
—
—
0
0
58
430
1.45
1.64
3.8
3.9
615.50
231.17
ng/l
0.50
46
349
32
208
1.61
1.64
1.9
1.7
—
—
—
0
0
216
2004
1.47
1.50
24.8
10.7
79.40
76.96
ml/min/173m2
1.14
204
1588
14
73
1.97
1.47
1.2
1.7
—
166.67
—
0
6
7
28
2.54
1.46
1.3
1.4
—
—
—
0
0
9
39
2.35
1.44
1.1
1.1
—
—
—
0
0
19
307
0.59
1.42
4.8
4.8
33.79
32.21
%
0.25
14
193
9
40
2.29
1.41
1.2
1.3
—
—
—
0
0
9
43
2.13
1.31
1.4
1.1
—
—
—
0
0
6
24
2.53
1.31
1.2
1.1
—
—
—
0
0
6
25
2.43
1.25
1.2
1.2
—
—
—
0
0
202
1872
1.36
1.24
28.0
13.0
39.96
40.00
%
0.03
141
1253
66
525
1.35
1.23
2.4
2.2
4243.82
10338.07
umol/l
0.67
57
449
8
37
2.20
1.22
1.3
1.3
—
—
—
0
0
30
207
1.51
1.22
4.5
3.0
—
—
—
0
0
17
102
1.71
1.19
1.6
1.5
—
—
—
0
0
14
79
1.82
1.19
1.4
1.2
—
—
—
0
0
5
21
2.41
1.09
1.4
1.5
—
—
—
0
0
7
32
2.22
1.09
1.0
1.1
—
17.17
—
0
6
102
878
1.27
1.05
3.5
3.6
20.53
38.12
ng/l
2.33
71
626
119
1045
1.26
1.03
3.4
3.6
0.00
0.02
estimate
0.50
23
179
9
49
1.87
0.99
3.2
2.1
25.96
25.13
mmol/l
—
9
41
5
23
2.20
0.98
1.2
1.3
—
—
—
0
0
10
54
1.89
0.98
2.7
1.5
0.93
0.91
nmol/l
—
10
42
204
2147
0.77
0.95
4.6
4.8
1.40
1.51
mmol/l
3.32
189
1955
117
1034
1.24
0.94
4.6
4.9
0.00
0.00
estimate
0.00
25
179
6
27
2.25
0.94
1.2
1.0
—
—
—
0
0
211
2210
0.76
0.93
5.0
5.5
2.58
2.76
mmol/l
2.18
194
2011
5
105
0.47
0.90
1.2
1.0
—
—
—
0
0
6
29
2.09
0.90
1.3
1.2
—
—
—
0
0
6
31
1.96
0.85
1.2
1.2
—
—
—
0
0
115
1024
1.22
0.84
3.5
3.6
0.00
0.00
estimate
0.00
25
185
8
47
1.72
0.81
1.0
1.3
—
—
—
0
0
198
2077
0.80
0.75
4.1
4.3
1.42
1.28
mmol/l
1.87
179
1875
5
25
2.02
0.73
1.4
1.2
—
—
—
0
0
207
2159
0.79
0.73
4.5
4.8
4.48
4.70
mmol/l
2.32
193
1979
65
553
1.23
0.72
4.1
3.7
0.00
0.00
estimate
0.00
21
177
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
5
27
1.87
0.69
1.0
1.1
—
—
—
0
0
5
27
1.87
0.69
1.4
1.2
—
—
—
0
0
99
885
1.19
0.67
2.5
2.2
76.71
79.52
nmol/l
0.42
94
772
36
289
1.29
0.65
1.4
1.4
—
—
—
0
0
58
494
1.22
0.64
2.2
2.1
3.75
3.13
mg/l
0.31
50
418
17
121
1.43
0.64
4.4
3.3
5.24
5.26
kpa
0.03
17
111
17
121
1.43
0.64
1.5
1.4
—
—
—
0
0
27
342
0.76
0.62
2.7
2.6
0.48
0.75
ug/l
3.22
18
223
0
20
0.00
0.60
0.0
1.1
—
1.24
—
0
9
0
21
0.00
0.60
0.0
1.2
—
94.40
—
0
5
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
176
1662
1.18
0.60
4.1
3.9
14.62
14.93
pmol/l
0.87
162
1493
50
586
0.82
0.60
3.8
4.0
1.49
2.13
ug/l
1.91
42
521
6
36
1.68
0.57
1.0
1.2
—
—
—
0
0
6
36
1.68
0.57
1.0
1.2
—
—
—
0
0
40
476
0.81
0.56
2.8
3.8
24.55
24.07
%
0.06
17
222
11
74
1.51
0.54
1.4
1.9
1.71
1.59
g/l
0.14
11
64
36
297
1.25
0.54
21.4
21.0
1.08
1.27
inr
—
5
43
6
39
1.55
0.53
1.5
1.4
—
—
—
0
0
7
47
1.50
0.48
1.0
1.3
—
—
—
0
0
43
369
1.20
0.46
1.2
1.3
44.08
47.53
iu/ml
0.05
12
120
68
609
1.16
0.44
1.6
1.7
1.48
1.39
mmol/l
0.41
59
514
7
51
1.38
0.44
1.1
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
82
750
1.14
0.40
3.9
4.0
8.46
6.02
mg/mmol
0.31
43
456
122
1148
1.12
0.37
2.8
2.6
—
—
—
0
0
142
1349
1.12
0.36
4.6
2.9
70.01
46.74
u/l
1.25
135
1238
87
804
1.12
0.36
3.7
3.7
—
—
—
0
0
20
164
1.24
0.34
2.9
2.1
53.33
62.87
ml/min/173m2
—
6
63
74
681
1.12
0.33
1.9
2.1
123.93
170.02
u/l
1.22
67
634
8
107
0.74
0.29
1.6
1.7
—
—
—
0
0
26
300
0.85
0.28
12.2
6.7
—
—
—
0
0
9
117
0.76
0.28
1.7
1.7
—
—
—
0
0
72
668
1.11
0.28
2.9
2.2
65.71
56.86
u/l
0.43
65
613
96
905
1.10
0.27
1.8
2.0
89.51
98.10
pmol/l
1.18
51
436
9
76
1.19
0.25
1.8
1.5
—
—
—
0
0
47
512
0.90
0.23
1.6
1.5
19.17
22.14
nmol/l
0.81
42
441
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
197
2008
0.92
0.19
5.0
4.8
1.71
2.55
mu/l
0.76
180
1807
6
52
1.16
0.19
1.0
1.2
—
2.97
—
0
6
50
468
1.08
0.16
1.5
1.8
498.08
436.80
pmol/l
0.81
39
381
8
71
1.13
0.16
1.9
1.5
—
—
—
0
0
83
864
0.94
0.14
2.3
2.6
123.39
113.31
ug/l
0.21
71
792
40
426
0.93
0.13
1.7
1.8
1139.33
1209.19
nmol/l
0.18
34
316
6
54
1.11
0.09
1.0
1.2
—
47.38
—
0
6
213
2148
0.95
0.07
5.0
4.8
6.24
6.02
mmol/l
1.51
197
1930
204
2058
0.96
0.07
6.4
6.2
41.40
40.38
mmol/mol
0.93
192
1897
44
457
0.96
0.07
1.3
1.3
1.53
2.23
u/ml
—
6
126
18
170
1.06
0.04
2.0
1.8
—
—
—
0
0
32
311
1.03
0.02
1.3
1.4
—
—
—
0
0
36
366
0.98
0.00
1.1
1.3
5.81
12.65
u/ml
0.60
15
144
10
101
0.99
0.00
1.0
1.4
—
—
—
0
0
11
115
0.95
0.00
2.3
2.2
1.04
1.20
%
0.41
11
115
0
9
0.00
0.00
0.0
1.7
—
35.91
—
0
9
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
1329.11
—
0
9
0
9
0.00
0.00
0.0
1.0
—
10.22
—
0
9
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
62
0.97
0.00
1.5
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
69
1.01
0.00
1.0
1.2
—
—
—
0
0
7
69
1.01
0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
8
79
1.01
0.00
4.1
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
6
68
0.88
0.00
1.0
1.2
—
25.25
—
0
6
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
6
65
0.92
0.00
1.0
1.2
—
3.13
—
0
16
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
5
49
1.02
0.00
2.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_LUNG_NEUROENDO_EXALLC – Neuroendocrine tumor and carcinoma of lung, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).